Surfactant mutations of the lung
ICD-10 J84.83 is a billable code used to indicate a diagnosis of surfactant mutations of the lung.
Surfactant mutations of the lung, classified under J84.83, refer to a group of genetic disorders that affect the production and function of surfactant proteins in the lungs. These proteins are crucial for reducing surface tension in the alveoli, preventing collapse during exhalation, and facilitating gas exchange. Clinically, patients may present with symptoms such as progressive dyspnea, cough, and hypoxemia, often leading to respiratory distress. The anatomy involved primarily includes the alveolar epithelium, where surfactant is produced by type II pneumocytes. Disease progression can vary, with some patients experiencing rapid deterioration and others showing a more chronic course. Diagnostic considerations include genetic testing for mutations in surfactant protein genes (e.g., SFTPB, SFTPC) and imaging studies like high-resolution CT scans that may reveal ground-glass opacities and reticular patterns indicative of surfactant dysfunction. Early diagnosis is critical for management, which may include supportive care, oxygen therapy, and in some cases, lung transplantation.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J84.83 covers conditions related to surfactant protein mutations, including surfactant protein B deficiency and surfactant protein C deficiency, which lead to interstitial lung disease and respiratory failure.
J84.83 should be used when a patient has a confirmed diagnosis of surfactant mutation-related lung disease, particularly when genetic testing has identified specific mutations, differentiating it from other interstitial lung diseases.
Documentation should include genetic test results confirming surfactant mutations, clinical notes detailing respiratory symptoms, imaging studies showing characteristic lung patterns, and any treatment plans initiated.
